Sandoz Generic Drug Settlement Claims Due November 9

Key facts

Settlement: Sandoz Inc. and Fougera Pharmaceuticals Inc. end-payer antitrust settlement
Settlement fund: $275 million, subject to the deductions and allocation approved by the court
Who may qualify: Consumers and other end payers who indirectly paid for any of 197 listed generic-drug groups from May 1, 2009 through December 31, 2019
Geography: Every state except Indiana and Ohio, plus the District of Columbia, Puerto Rico and the U.S. Virgin Islands
Consumer proof rule: At least one purchase record for each drug claimed
Claim deadline: November 9, 2026
Court: U.S. District Court for the Eastern District of Pennsylvania
Case: In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724
Status: The court granted final approval in September 2025. The consumer claims process is now open.

What changed

Consumers can now submit claims in a $275 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. over allegations that generic-drug manufacturers conspired to raise prices and reduce competition. The official settlement website says claims must be filed online or mailed with a postmark no later than November 9, 2026.

The settlement is part of a large federal multidistrict litigation, or MDL, in the Eastern District of Pennsylvania. An MDL places related federal lawsuits before one judge for coordinated pretrial work. The case combines claims involving many generic medicines, manufacturers and purchasers. This settlement resolves the end-payer plaintiffs' claims against Sandoz and Fougera. It does not resolve every claim against every company in the broader litigation.

The court granted final approval after a July 2025 fairness hearing. In a September 26, 2025 opinion, U.S. District Judge Cynthia M. Rufe certified the settlement class and found the agreement fair, reasonable and adequate. The current consumer form covers claims under the Sandoz settlement and a separate Sun/Taro settlement. Consumers should identify the listed drugs they bought and let the administrator apply the correct settlement rules.

Deadline to act

Consumer claims must be submitted online or postmarked by November 9, 2026. The court-authorized administrator, not Class Action Pulse, decides whether a claim is valid.

Who may qualify

The Sandoz settlement class includes people and entities that indirectly purchased, paid for or reimbursed some or all of the price of a covered generic drug from May 1, 2009 through December 31, 2019. An indirect purchase generally means the medicine was obtained through a pharmacy or another intermediary rather than bought directly from a defendant manufacturer.

The class covers every state except Indiana and Ohio. It also covers the District of Columbia, Puerto Rico and the U.S. Virgin Islands. A consumer must have paid at least part of the cost of a listed drug, such as a cash price, copayment or coinsurance amount. The form asks consumers to report the total amount they paid out of pocket, not the portion paid by an insurer.

The class excludes consumers whose relevant purchases were covered by Medicaid. It also excludes direct purchases from defendants, purchases made for resale, defendants and certain related people or entities, the judges assigned to the case and their immediate families, and people who validly excluded themselves from the settlement. The exclusion deadline has already passed.

A person can have some covered purchases and some excluded purchases. The settlement agreement says that person remains in the class only for purchases that meet the class definition. Consumers should not include a drug merely because they took it during the class period. The product, formulation, purchase date, location and payment method must fit the official rules.

The date range is only the first test

A purchase between 2009 and 2019 is not enough by itself. The drug must appear on the official list, and the claimant must satisfy the settlement's geographic, payment and documentation rules.

Which generic drugs are covered

The consumer claim form lists 197 numbered drug groups, often with several formulations or strengths under one number. The list includes widely used medicines such as albuterol, amitriptyline, azithromycin, baclofen, buspirone, celecoxib, ciprofloxacin, doxycycline, fluconazole, gabapentin, glimepiride, levothyroxine, metformin extended release, prednisone, propranolol, trazodone and warfarin. It also includes topical drugs, eye medicines, injectable products and other prescription treatments.

The exact formulation matters. For example, the appendix may list particular tablet strengths, extended-release versions, creams, ointments, solutions or capsules. Consumers should use the complete Appendix A attached to the official claim form or the drug lookup tool on the settlement website. A familiar drug name in this article is only an example and does not replace the official product list.

The claim form asks for the list number, generic-drug name and total amount the consumer paid for that drug during the covered period. If the person bought multiple listed formulations under the same drug group, the instructions say to combine the amount paid for those formulations.

What the lawsuit alleged

The end-payer plaintiffs alleged that Sandoz and other generic-drug manufacturers participated in schemes to fix or stabilize prices, rig bids, and allocate markets or customers. Price fixing means competitors allegedly agreed on price or price-related conduct rather than making independent decisions. Bid rigging means competitors allegedly coordinated bids instead of competing honestly. Market allocation means competitors allegedly divided customers, products or business opportunities.

The plaintiffs claimed that this conduct caused consumers, health plans and other end payers to pay more for covered generic drugs than they would have paid in a competitive market. Their claims invoked federal and state antitrust laws, consumer-protection laws and common-law theories.

Sandoz denied liability and stated that it had defenses. The settlement agreement says Sandoz entered the deal to avoid the expense and burden of continued litigation and to resolve the claims against it. A settlement is not an admission that the allegations are true. The court's approval found the negotiated resolution fair for the class. It did not decide at trial that Sandoz or Fougera committed every act alleged.

The federal court also considered objections from state attorneys general who were concerned about consumer documentation requirements and the effect of the settlement on state enforcement claims. The court concluded that consumers need only show one qualifying payment record for each drug they claim, not proof of every purchase of that drug. The court found that requirement reasonable as a fraud-control measure and approved the proportional allocation method.

Who Sandoz and Fougera are in this case

Sandoz Inc. is a generic-drug manufacturer named as a defendant in the coordinated litigation. Fougera Pharmaceuticals Inc. is included with Sandoz as a settling defendant. The settlement agreement treats the two companies collectively as Sandoz for purposes of the deal and defines the released Sandoz parties to include related entities.

The settlement applies to the end-payer claims against those settling parties. Other manufacturers remain separate defendants or settling parties under their own agreements. That distinction matters because the official consumer form can cover both the Sandoz settlement and the separate Sun/Taro settlement. A claimant does not need to decide legal responsibility among manufacturers. The claimant must accurately identify covered purchases and submit the requested proof.

How the consumer claim works

Consumers may file online through GenericDrugsEndPayerSettlement.com or mail the official paper form to the administrator. The paper form lists the administrator as A.B. Data, Ltd., P.O. Box 173118, Milwaukee, Wisconsin 53217. The official toll-free number is 1-877-316-0171.

The form requires contact information, a preferred payment method, confirmation of class membership, the covered drugs purchased, the amount paid out of pocket, documentation and a signed certification. Available payment choices on the form include ACH direct deposit, Zelle, PayPal, Venmo and a paper check. Payment selection does not guarantee that a claim will be approved or establish the amount.

For each listed drug claimed, the consumer must provide a document showing at least one purchase between May 1, 2009 and December 31, 2019. The form gives examples that include a receipt or invoice, an account statement, an itemized pharmacy purchase record, or another record showing the drug, date and amount paid. A person claiming albuterol and doxycycline, for example, needs at least one qualifying purchase record for albuterol and at least one for doxycycline.

The court explained that once a consumer establishes one payment for a particular drug, the consumer may claim the other qualifying payments made for that drug. The administrator may audit a claim or ask for more support. If a claim is rejected or reduced, the form describes a review process with short response periods. Claimants should therefore keep copies of the form, supporting records and submission confirmation.

Ask the pharmacy for history early

The court record recognizes that old prescription documentation may take effort to obtain. A pharmacy purchase history, insurer record or receipt may help, but only the administrator can decide whether a particular document is sufficient.

How payments will be calculated

The settlement does not promise a fixed amount to each consumer. The court approved a proportional, or pro rata, distribution. That means an approved claimant's share depends on the claimant's covered spending compared with the covered spending submitted by other approved claimants.

The $275 million fund is not the same as the amount available for direct consumer checks. The court record identifies potential deductions for attorneys' fees, litigation expenses, class-representative awards, notice and administration. The settlement agreement also allowed a reduction tied to valid opt-outs. The final amount available for claims is then shared among consumers and third-party payers under the approved allocation rules.

Because the administrator does not yet know the total value of all valid claims, the official materials do not state a guaranteed consumer payment or a reliable percentage of each person's spending. Headlines that divide $275 million by an assumed number of people ignore the allocation between consumer and institutional claims, court-approved deductions and differences in covered spending.

No fixed check is verified

Payment is proportional to validated covered spending and the overall claims pool. The official record does not support a guaranteed minimum or an estimated check for an individual claimant.

Case timeline and current status

May 1, 2009: Covered purchase period begins.
December 31, 2019: Covered purchase period ends.
2016: The federal generic-drug pricing MDL begins in the Eastern District of Pennsylvania.
February 2025: The court grants preliminary approval to the Sandoz settlement.
July 23, 2025: The court holds the final fairness hearing.
September 26, 2025: The court issues an opinion approving the settlement and certifying the settlement class.
October 2025: The court corrects part of the list of entities that had excluded themselves.
2026: The official consumer claims process opens for the Sandoz and Sun/Taro settlements.
November 9, 2026: Consumer claim deadline.

The Sandoz settlement is final-approved, but claims still require review and calculation. Payments cannot be calculated until the administrator processes the claims and the distribution requirements are met. The larger generic-drug pricing litigation also continues against parties not resolved by this agreement.

The Class Action Pulse article about the separate multistate attorney general claims process has a different deadline and different official administrator. Readers should not assume that filing one generic-drug claim automatically files the other. See Generic Drug Price-Fixing Settlements: Claims Due March 8, 2027 for that separate process.

Evidence boundaries and unresolved questions

The settlement agreement records allegations of coordinated pricing and competition-related conduct. Sandoz denied liability, and no trial verdict established every allegation against the settling companies. The court approved the settlement based on class-certification and fairness standards, including litigation risk, the size of the fund and the proportional allocation plan.

The final individual payment remains unknown. It depends on valid claims, covered spending, allocation between claimant types and approved deductions. The public materials reviewed for this article do not provide a consumer payment calculator that can produce a reliable estimate before claims are processed.

The official form combines the Sandoz and Sun/Taro consumer claims process. The $275 million figure in this article refers to the Sandoz and Fougera end-payer settlement. Claimants should use the administrator's form and covered-drug list rather than attempting to assign a purchase to one manufacturer on their own.

Frequently asked questions

Who can file a Sandoz generic-drug settlement claim?

Consumers may qualify if they indirectly paid for a listed generic drug from May 1, 2009 through December 31, 2019 in a covered jurisdiction and do not fall within an exclusion. Indiana and Ohio are excluded, and Medicaid-covered purchases are not eligible.

What is the deadline?

The official settlement website and consumer form list November 9, 2026. Online claims must be submitted by that date. Mailed claims must be postmarked by that date.

Do I need proof?

Yes. The consumer form requires at least one qualifying purchase document for each drug claimed. The administrator may request more information or audit claims.

How much could I receive?

There is no fixed verified amount. Approved claims are paid proportionally based on covered spending and the total approved claims, after the court-approved deductions and allocation rules are applied.

Are all generic drugs included?

No. The claim form contains a specific list of 197 numbered drug groups and their covered formulations or strengths. Use the official appendix or lookup tool.

Did Sandoz admit wrongdoing?

No. Sandoz denied liability. The settlement resolves the end-payer claims against Sandoz and Fougera without a trial verdict on every allegation.

Is this the same as the March 8, 2027 state attorney general claim process?

No. The processes concern related generic-drug price-fixing allegations but use different settlements, administrators and deadlines. Consumers should review each official site separately.

Where should I file?

Use GenericDrugsEndPayerSettlement.com or the court-authorized paper form. Do not send prescription, insurance or payment records to Class Action Pulse.